Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 20,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood sample Clear all
Recruiting Phase 1Phase 2 Interventional

Use of Phenylephrine for Assessment of Mitral Regurgitation Severity

NCT04500899
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Mydfrin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 19, 2026, 1:03 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Rapid HCV RNA Testing and LInkage to Care

NCT04302948
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
HCV RNA screening
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional Results available

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

NCT01640171
View directory record Official record
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 19, 2026, 1:03 PM EDT
Terminated Not applicable Interventional Results available

Moderated Blood Flow Restriction After Anterior Cruciate Ligament Reconstruction

NCT02911909
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear
Interventions
Delfi, Standard rehabilitation
Device · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 19, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery

NCT02097732
View directory record Official record
Conditions
Metastatic Melanoma, Brain Metastases
Interventions
Ipilimumab, Stereotactic Radiosurgery
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 19, 2026, 1:03 PM EDT
Recruiting Phase 1 Interventional

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563
View directory record Official record
Conditions
Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma
Interventions
azacitidine, abatacept
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients

NCT05081063
View directory record Official record
Conditions
Hemorrhagic Shock, Acute Blood Loss Anemia, Traumatic Brain Injury
Interventions
Routine labs
Combination Product
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Male only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Orthostatic, Respiratory, Balance-Intervention

NCT04210063
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Inspiratory Muscle Training (IMT)
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 19, 2026, 1:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

NCT05432804
View directory record Official record
Conditions
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Placebo Administration, Selinexor, Temozolomide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 1:03 PM EDT
Recruiting Phase 3 Interventional

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006
View directory record Official record
Conditions
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Results available

Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma

NCT03615404
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme, Pediatric Brain Tumor, Recurrent, Pediatric Brain Tumor
Interventions
CMV-DCs with GM-CSF, Td (tetanus toxoid)
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
0 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 19, 2026, 1:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

NCT01050504
View directory record Official record
Conditions
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Recurrent Bladder Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Results available

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C), Cellectra 2000
Drug · Radiation · Device
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 19, 2026, 1:03 PM EDT
Terminated No phase listed Observational

A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456

NCT04008849
View directory record Official record
Conditions
Inherited Metabolic Disorders (IMD)
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Magenta Therapeutics, Inc.
Industry
Eligibility
Up to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 19, 2026, 1:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adipose Tissue and Immune Activation in HIV

NCT04439448
View directory record Official record
Conditions
Human Immunodeficiency Virus, Obesity
Interventions
dual-energy X-ray absorptiometry (DEXA) scan, Carotid and branchial artery ultrasound, 2-hour oral glucose tolerace test, Blood collection
Radiation · Other · Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 19, 2026, 1:03 PM EDT
Active, not recruiting Phase 2 Interventional

Renal Mechanism of SGLT2 Inhibition

NCT05507892
View directory record Official record
Conditions
Type 2 Diabetes, Diabetic Kidney Disease
Interventions
canagliflozin, Aminohippurate Sodium Inj 20%
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

NCT00790036
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Everolimus, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
34
States / cities
Chandler, Arizona • Fayetteville, Arkansas • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 19, 2026, 1:03 PM EDT
Completed No phase listed Observational

A Screening Study Targeting Tumor-specific Antigens

NCT05158621
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
Interventions
blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
Procedure
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • East Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 19, 2026, 1:03 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Allo HSCT for High Risk Hemoglobinopathies

NCT06872333
View directory record Official record
Conditions
Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Interventions
Alemtuzumab, Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Cyclophosphamide, Sirolimus, Tacrolimus, Mycophenolate Mofetil, Plerixafor (mozobil)
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional

OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)

NCT02814552
View directory record Official record
Conditions
High Blood Pressure
Interventions
HTN PRA App, Blood Sample
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Macclenny, Florida • Old Town, Florida • Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 19, 2026, 1:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Tissue Repository: CTCL Collection Protocol

NCT02840747
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Sézary Syndrome
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 19, 2026, 1:03 PM EDT
Approved For Marketing No phase listed Expanded access

SynCardia Freedom Driver System Study

NCT00733447
View directory record Official record
Conditions
Biventricular Failure
Interventions
CardioWest temporary Total Artificial Heart (TAH-t) System
Device
Lead sponsor
SynCardia Systems. LLC
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 19, 2026, 1:03 PM EDT
Terminated Not applicable Interventional Results available

Campath Maintenance in Chronic Lymphocytic Leukemia

NCT00587847
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Campath
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 19, 2026, 1:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Brain Health in Transgender Adults

NCT07624747
View directory record Official record
Conditions
Gender Dysphoria
Interventions
Magnetic Resonance Imaging, Cognition and Health Tests, Optional Exercise Test
Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 19, 2026, 1:03 PM EDT